Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. // Neuropsychopharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0893133X26036171?dgcid=rss_sd_all
Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology. https://www.sciencedirect.com/science/article/pii/S0893133X26036171?dgcid=rss_sd_all
“Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.” Neuropsychopharmacology.
@article{article60297,
title = {Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia},
journal = {Neuropsychopharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0893133X26036171?dgcid=rss_sd_all}
}